65,437 trials
Blood Pressure
Primary: Percent of Subjects With a Greater Than 20% Decrease in Systolic Blood Pressure (SBP) Following Induction of General Anesthesia — 48; 12; 67; 39 Percentage of subjects…
Heart Failure
Primary: Compare the Time to Initiation of Clinical Action Prompted by an OptiVol Threshold Crossing Between Monthly and Quarterly Review of Cardiac Compass Trends With OptiVol…
Healthy Volunteers
Primary: Maximum Observed Plasma Concentration (Cmax) — 2059.6; 1963.1; 1799.9; 2048.5 ng/mL
Ischemia
Primary: Digital Micro-vascular Flow — .11; .18; -.01; -.06 perfusion unit
Crohn's Disease
Primary: Safety and Tolerability of Ciprofloxacin — 25; 11; 9; 1 Adverse events
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Trough Forced Expiratory Volume In One Second (FEV1) After 26 Weeks of Treatment — 1.45; 1.38; 1.36 Liters
In-stent Coronary Artery Restenosis
Primary: In-stent Late Lumen Loss — 0.07 mm
Headache
Primary: Time to Relief (Min) — 92.2; 83.9; 35.4 Minutes
Urinary Incontinence
Primary: Percentage of Participants With a Decrease in Leakage Events of 30% or More. — 60.6; 61.7 Percentage of participants — p=.92
Common Variable Immunodeficiency · Agammaglobulinemia
Primary: Proportion of Patients Achieving Immunoglobulin G (IgG) Levels ≥ 5 g/L on Day 12 — 0.944 proportion of patients
Leukapheresis
Primary: Mononuclear Cell Collection Efficiency — 61; 57 % of processed MNCs that were collected
Osteoarthritis
Primary: Numeric Pain Score — 0.67; 1.6; 2.5; 3.6 units on a scale — p=<0.05
Schizophrenia
Primary: Change in Positive and Negative Syndrome Scale (PANSS) Measures Symptoms of Schizophrenia — 95; 75 scores on a scale
Chronic Hepatitis c
Primary: Sustained Virologic Response — 24; 25 participants
Healthy Volunteers
Primary: Cmax (the Maximum Observed Plasma Concentration) — 1147.9 ng/mL